G-CSF vs GM-CSF in hospitalized neutropenic patients: a randomized trial (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

G-CSF vs GM-CSF in hospitalized neutropenic patients: a randomized trial (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A1550 1993. Unique Identifier : AIDSLINE ICDB/94695948
Malamud S; Perentesis V; Div. of Hematology-Oncology, Dept. of Medicine, Beth Israel; Medical Center, New York, NY 10003

Abstract: G-CSF and GM-CSF are widely used biological agents in the treatment of neutropenia (NP) due to cancer chemotherapy (CT) and the acquired immunodeficiency syndrome (AIDS). Although recommended as prophylaxis for neutropenia, most hospitalized patients (pts) are treated during the neutropenic episode. This randomized trial was to determine if any significant clinical differences exist between G-CSF-and GM-CSF in the hospitalized pt. 50 neutropenic pts with either CT-NP or AIDS-NP were randomized to receive either a fixed-dose of G-CSF (300 ug/day sc) or GM-CSF (250 ug/day sc). Data on 20 G-CSF and 8 GM-CSF is available for analysis. Of 20 G-CSF pts, neutropenia was due to AIDS in 10, CT in 8, both in 1, and 1 other. Mean number of treatment days: 11.9 (4-36). Mean granulocyte nadir 1200/mm3 (100-10,500), mean platelet nadir 91/mm3 (1-220). Mean number of days on antibiotics 24.9 (0-90). GM-CSF pts included 4 with AIDS, 3 with CT, and 1 both. Mean number of treatment days: 13.4 (2-62). Mean granulocyte nadir 868/mm3 (600-13,500). Mean platelet nadir 148/mm3 (40-241). Mean number of days on antibiotics 20.4 (0-100). One G-CSF pt developed bone pain. No other toxicity occurred. No clinically significant difference was observed between G-CSF and GM-CSF. Seven pts receiving G-CSF developed worsening thrombocytopenia on treatment and this was not noted with GM-CSF. However, a causal relationship could not be established. AIDS pts generally received longer courses of G-CSF or GM-CSF without influence on the number of antibiotic treatment days. These agents appear equally effective at a fixed dose schedule in both AIDS and chemotherapy-related neutropenia.

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/THERAPY Antineoplastic Agents/*ADVERSE EFFECTS/THERAPEUTIC USE Comparative Study Drug Administration Schedule Granulocyte Colony-Stimulating Factor/*ADMINISTRATION & DOSAGE Granulocyte-Macrophage Colony-Stimulating Factor/*ADMINISTRATION & DOSAGE Granulocytes/DRUG EFFECTS *Hospitalization Human Leukocyte Count/DRUG EFFECTS Neutropenia/CHEMICALLY INDUCED/IMMUNOLOGY/*THERAPY ABSTRACT RANDOMIZED CONTROLLED TRIAL CLINICAL TRIAL
940228
M9420817

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .